Notably, exploratory analyses of large outcome trials have reported a substantially lower incidence of new-onset OSA among participants treated with SGLT2 inhibitors compared to placebo (approximately 50% relative risk reduction) [103]. This evidence concerns the gene SLC5A2 and obstructive sleep apnea syndrome.